Expediting Viral Vaccine Development for Covid-19: Integrated Media/Buffers Solutions and Testing for Virus Expression
As the world searches for a way to end the coronavirus pandemic, government bodies, academic collaborations and pharma companies race to produce effective new therapies and vaccine candidates for COVID-19. With more than 115 companies actively engaged in this endeavour, we see approximately 10% of these vaccine candidates focused on viral vaccine expression systems. Speed to clinic is of paramount importance; however, as producing a commercial vaccine can take many years, how can we accelerate vaccine development with speed and safety in mind?
To meet these challenges in a pandemic situation, you can benefit from our rapid platform approaches for your cell line and virus seed testing, our media manufacturing network, and our scalable single use process solutions and process monitoring tools to simplify progression and ensure rapid release of your drug product.
- Sartorius integrated cell line testing, viral vaccine testing, media manufacturing & single-use manufacturing solution specific to viral vaccine manufacture
- Sartorius as a secured supply chain of media, buffer
- How to use rapid testing methods to accelerate the manufacturing process
- Navigate through a wide range of lot release testing offerings
Meet Our Expert
Érica Schulze, PhD
Product Management Vaccine l Viral Vector
Érica Schulze PhD, was appointed several research associate positions throughout her academic career in Brazil, Canada and Germany, in which she worked with mammalian cell culture for the process development of vaccines, recombinant proteins and gene therapeutics. She worked as Media Application Specialist at Sartorius Stedim Biotech in Germany to support customers in cell culture media applications for the production of biopharmaceuticals in EMEA. In 2018 she was assigned the role of Product Manager for Cell Culture Media to support Vaccine Applications worldwide. She is responsible to set the feature definition for vaccine product lines and for guiding the success of these products.